Prognostic and predictive markers in hematologic neoplasms. A review

Polish Journal of Pathology

Volumn 62, Issue 4, 2011, Pages 189-205

  Gorczyca, Wojciech ^a  

^a CSI Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

AGE; HUMAN; LEUKEMIA; LYMPHOMA; METABOLISM; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

AGE FACTORS; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA; LYMPHOMA; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84855774004     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (232)

1. Bassan R, Gatta G, Tondini C, Willemze R. Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hematol 2004; 50: 223-261.
2. Cairo MS, Sposto R, Perkins SL, et al. Burkitt's and Burkittlike lymphoma in children and adolescents: a review of the Children's Cancer Group experience. Br J Haematol 2003; 120: 660-670.
3. Piris MA, Arribas A, Mollejo M. Marginal zone lymphoma. Semin Diagn Pathol 2011; 28: 135-145.
4. Traverse-Glehen A, Baseggio L, Salles G, et al. Splenic marginal zone B-cell lymphoma: a distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification. Curr Opin Oncol 2011; 23: 441-448.
5. Phekoo KJ, Schey SA, Richards MA, et al. A population study to define the incidence and survival of multiple myeloma in a NationalHealth Service Region in UK. Br J Haematol 2004; 127: 299-304.
6. van Doorn R, Van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309Dutch patients. Arch Dermatol 2000; 136: 504-510.
7. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: longterm survival in 489 patients. J Am Acad Dermatol 1999; 40: 418-425.
8. Rodriguez J, McLaughlin P, Hagemeister FB, et al. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 1999; 93: 2202-2207.
9. Hans CP, Weisenburger DD, Vose JM, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003; 101: 2363-2367.
10. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the EuropeanMCL Network. Br J Haematol 2005; 131: 29-38.
11. Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997; 89: 2067-2078.
12. Robertson LE, PughW, O'Brien S, et al. Richter's syndrome: a report on 39 patients. J Clin Oncol 1993; 11: 1985-1989.
13. Beà S, López-Guillermo A, RibasM, et al. Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome). Am J Pathol 2002; 161: 957-968.
14. Nakamura N, Abe M. Richter syndrome in B-cell chronic lymphocytic leukemia. Pathol Int 2003; 53: 195-203.
15. Tsimberidou AM, KeatingMJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 2005; 103: 216-228.
16. Tsimberidou AM, Keating MJ. Richter's transformation in chronic lymphocytic leukemia. Semin Oncol 2006; 33: 250-256.
17. Kjeldsberg CR, Marty J. Prolymphocytic transformation of chronic lymphocytic leukemia. Cancer 1981; 48: 2447-2457.
18. Enno A, Catovsky D, O'Brien M, et al. 'Prolymphocytoid' transformation of chronic lymphocytic leukaemia. Br J Haematol 1979; 41: 9-18.
19. Pugh WC, Manning JT, Butler JJ. Paraimmunoblastic variant of small lymphocytic lymphoma/leukemia. AmJ Surg Pathol 1988; 12: 907-917.
20. Ohno T, Smir BN, Weisenburger DD, et al. Origin of the Hodgkin/Reed-Sternberg cells in chronic lymphocytic leukemia with 'Hodgkin's transformation'. Blood 1998; 91: 1757-1761.
21. Williams J, Schned A, Cotelingam JD, Jaffe ES. Chronic lymphocytic leukemia with coexistent Hodgkin's disease. Implications for the origin of the Reed-Sternberg cell. Am J Surg Pathol 1991; 15: 33-42.
22. Brecher M, Banks PM. Hodgkin's disease variant of Richter's syndrome. Report of eight cases. Am J Clin Pathol 1990; 93: 333-339.
23. Momose H, Jaffe ES, Shin SS, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma with Reed-Sternberg- like cells and possible transformation to Hodgkin's disease. Mediation by Epstein-Barr virus. Am J Surg Pathol 1992; 16: 859-867.
24. Kanzler H, Küppers R, Helmes S, et al. Hodgkin and Reed- Sternberg-like cells in B-cell chronic lymphocytic leukemia represent the outgrowth of single germinal-center B-cellderived clones: potential precursors ofHodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood 2000; 95: 1023-1031.
25. Wiernik PH. Second neoplasms in patients with chronic lymphocytic leukemia. Curr TreatOptionsOncol 2004; 5: 215-223.
26. Ansell SM, Li CY, Lloyd RV, Phyliky RL. Epstein-Barr virus infection in Richter's transformation. Am J Hematol 1999; 60: 99-104.
27. Harousseau JL, Flandrin G, Tricot G, et al. Malignant lymphoma supervening in chronic lymphocytic leukemia and related disorders. Richter's syndrome: a study of 25 cases. Cancer 1981; 48: 1302-1308.
28. Travis LB, Curtis RE, Boice JD Jr, et al. Second cancers following non-Hodgkin's lymphoma. Cancer 1991; 67: 2002-2009.
29. Torelli UL, Torelli GM, Emilia G, et al. Simultaneously increased expression of the c-myc and mu chain genes in the acute blastic transformation of a chronic lymphocytic leukaemia. Br J Haematol 1987; 65: 165-170.
30. Tsimberidou AM, O'Brien S, Kantarjian HM, et al. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 2006; 107: 1294-1302
31. Tsimberidou AM, O'Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J ClinOncol 2006; 24: 2343-2351.
32. de Leval L, Vivario M, De Prijck B, et al. Distinct clonal origin in two cases of Hodgkin's lymphoma variant of Richter's syndrome associated With EBV infection. Am J Surg Pathol 2004; 28: 679-686.
33. Fayad L, Robertson LE, O'Brien S, et al. Hodgkin's disease variant of Richter's syndrome: experience at a single institution. Leuk Lymphoma 1996; 23: 333-337.
34. Weisenberg E, Anastasi J, Adeyanju M, et al. Hodgkin's disease associated with chronic lymphocytic leukemia. Eight additional cases, including two of the nodular lymphocyte predominant type. Am J Clin Pathol 1995; 103: 479-484.
35. Tsang WY, Chan JK, Sing C. The nature of Reed-Sternberglike cells in chronic lymphocytic leukemia. Am J Clin Pathol 1993; 99: 317-323.
36. Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997; 15: 1587-1594.
37. Ersbøll J, Schultz HB, Pedersen-Bjergaard J, Nissen NI. Follicular low-grade non-Hodgkin's lymphoma: long-term outcome with or without tumor progression. Eur JHaematol 1989; 42: 155-163.
38. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311: 1471-1475.
39. Feller AC, Diebold J. Histopathology of nodal and extranodal non-Hodgkin's lymphomas. 3rd ed. Springer-Verlag, BerlinHeidelberg 2004.
40. Lee JT, Innes DJ Jr, Williams ME. Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin's lymphoma. J Clin Invest 1989; 84: 1454-1459.
41. Natkunam Y, Warnke RA, Zehnder JL, et al., Blastic/blastoid transformation of follicular lymphoma: immunohistologic and molecular analyses of five cases. Am J Surg Pathol 2000; 24: 525-534.
42. De Jong D, Voetdijk BM, Beverstock GC, et al. Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N Engl J Med 1988; 318: 1373-1378.
43. Kroft SH, Domiati-Saad R, Finn WG, et al. Precursor B-lymphoblastic transformation of grade I follicle center lymphoma. Am J Clin Pathol 2000; 113: 411-418.
44. Kojima M, Inagaki H, Motoori T, et al. Clinical implications of nodalmarginal zone B-cell lymphoma among Japanese: study of 65 cases. Cancer Sci 2007; 98: 44-49.
45. Diamandidou E, Colome-Grimmer M, Fayad L, et al. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998; 92: 1150-1159.
46. Salhany KE, Cousar JB, Greer JP, et al. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. Am J Pathol 1988; 132: 265-277.
47. Vergier B, deMuret A, Beylot-Barry M, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood 2000; 95: 2212-2218.
48. Arulogun SO, Prince HM, Ng J, et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood 2008; 112: 3082-3087.
49. Edinger JT, Clark BZ, Pucevich BE, et al. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol 2009; 33: 1860-1868.
50. Cerroni L, Rieger E, Hödl S, Kerl H. Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma. Am J Surg Pathol 1992; 16: 543-552.
51. Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, longtermcomplication rates, and prognostic factors.Mayo Clin Proc 2006; 81: 159-166.
52. Tefferi A. Essential thrombocythemia: scientific advances and current practice. Curr Opin Hematol 2006; 13: 93-98.
53. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21: 270-276.
54. Cervantes F, Tassies D, Salgado C, et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 1991; 85: 124-127.
55. Chim CS, Kwong YL, Lie AK, et al. Long-termoutcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med 2005; 165: 2651-2658.
56. De Sanctis V, Mazzucconi MG, Spadea A, et al. Long-termevaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution. Br J Haematol 2003; 123: 517-521.
57. Passamonti F, Rumi E, Arcaini L, et al. Blast phase of essential thrombocythemia: A single center study. Am J Hematol 2009; 84: 641-644.
58. Ríos R, Solé F, del Mar Pérez M, et al. t(2;3) in a case of blastic transformation of essential thrombocythaemia. Br J Haematol 1996; 92: 769-770.
59. Paolini R, Bonaldi L, Bianchini E, et al. Spontaneous evolution of essential thrombocythaemia into acute megakaryoblastic leukaemia with trisomy 8, trisomy 21 and cutaneous involvement. Eur J Haematol 2003; 71: 466-469.
60. Hirose Y, Masaki Y, Sugai S. Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases. Eur J Haematol 2002; 68: 112-116.
61. Hsiao HH, Ito Y, Sashida G, et al. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia. Leuk Res 2005; 29: 1247-1252.
62. Sterkers Y, Preudhomme C, Laï JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91: 616-622.
63. Lazarevic VLj, Tomin D, Jankovic GM, et al. A novel t(2;17) in transformation of essential thrombocythemia to acutemyelocytic leukemia. Cancer Genet Cytogenet 2004; 148: 77-79.
64. Emilia G, Sacchi S, Temperani P, et al. Progression of essential thrombocythemia to blastic crisis via idiopathic myelofibrosis. Leuk Lymphoma 1993; 9: 423-426.
65. Gaidano G, Pastore C, Santini V, et al. Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia. Genes Chromosomes Cancer 1997; 19: 250-255.
66. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981; 304: 441-447.
67. Najean Y, Rain JD. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol 1997; 34: 6-16.
68. Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997; 34: 17-23.
69. Swolin B, Weinfeld A, Westin J. A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 1988; 72: 386-395.
70. Kiladjian JJ, Gardin C, Renoux M, et al. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol J 2003; 4: 198-207.
71. Fruchtman SM, Petitt RM, Gilbert HS, et al. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 2005; 29: 481-491.
72. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005; 105: 2664-2670.
73. Nachtkamp K, Kündgen A, Strupp C, et al. Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res 2009; 33: 1024-1028.
74. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusiondependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011; 118: 3765-3776.
75. Klapper W, Hoster E, Rölver L, et al., Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. J Clin Oncol 2007; 25: 3330-3336.
76. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159-2169.
77. Yoon DH, Koh YW, Kang HJ, et al. CD68 and CD163 as prognostic factors for Korean patients withHodgkin lymphoma. Eur J Haematol 2011 Nov 2. doi: 10.1111/j.1600-0609.2011. 01731.x. [Epub ahead of print].
78. Zaki MA, Wada N, Ikeda J, et al. Prognostic implication of types of tumor-associatedmacrophages inHodgkin lymphoma. Virchows Arch 2011; 459: 361-366.
79. Kamper P, Bendix K, Hamilton-Dutoit S, et al. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein- Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011; 96: 269-276.
80. Canioni D, Brice P, Lepage E, et al. Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study fromthe Groupe d'Etude des Lymphomes Folliculaires. Br J Haematol 2004; 126: 364-371.
81. Rozman C, Montserrat E, Rodríguez-Fernández JM, et al. Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984; 64: 642-648.
82. Mauro FR, De Rossi G, Burgio VL, et al. Prognostic value of bone marrow histology in chronic lymphocytic leukemia. A study of 335 untreated cases froma single institution.Haematologica 1994; 79: 334-341.
83. Pangalis GA, Roussou PA, Kittas C, et al. Patterns of bonemarrow involvement in chronic lymphocytic leukemia and small lymphocytic (well differentiated) non-Hodgkin's lymphoma. Its clinical significance in relation to their differential diagnosis and prognosis. Cancer 1984; 54: 702-708.
84. Geisler C, Ralfkiaer E, Hansen MM, et al. The bone marrow histological pattern has independent prognostic value in early stage chronic lymphocytic leukaemia. Br J Haematol 1986; 62: 47-54.
85. Geisler CH, Hou-Jensen K, Jensen OM, et al. The bone-marrow infiltration pattern in B-cell chronic lymphocytic leukemia is not an important prognostic factor. Danish CLL Study Group. Eur J Haematol 1996; 57: 292-300.
86. Oudat R, Keating MJ, Lerner S, et al. Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission. Leukemia 2002; 16: 632-635.
87. Schade U, Bock O, Vornhusen S, et al. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70). Hum Pathol 2006; 37: 1153-1161.
88. Arcaini L, Burcheri S, Rossi A, et al. Nongastric marginalzone B-cellMALT lymphoma: prognostic value of disease dissemination. Oncologist 2006; 11: 285-291.
89. Specht L, Nissen NI. Prognostic factors in Hodgkin's disease stage IV. Eur J Haematol 1988; 41: 359-367.
90. Specht L, Nissen NI. Prognostic factors in Hodgkin's disease stage III with special reference to tumour burden. Eur JHaematol 1988; 41: 80-87.
91. Dingli D, Kyle RA, Rajkumar SV, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 2006; 108: 1979-1983.
92. Cesana C, Klersy C, Brando B, et al. Prognostic value of circulating CD34+cells in myelodysplastic syndromes. Leuk Res 2008; 32: 1715-1723.
93. Patnaik MM, Lasho TL, Finke CM, et al. Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients. AmJHematol 2011; 86: 393-398.
94. Matsushima T, Handa H, Yokohama A, et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 2003; 101: 3386-3390.
95. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009; 523-531.
96. WHO classification of tumors of haematopoietic and lymphoid tissues. Swerdlow SH, Campo E, Harris NL, et al. (ed.). IARC, Lyon 2008.
97. Carbone A, Santoro A. How I treat: diagnosing and managing "in situ" lymphoma. Blood 2011; 117: 3954-3960.
98. Lamant L, de Reyniès A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 2007; 109: 2156-2164.
99. Gascoyne RD, Lamant L, Martin-Subero JI, et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 2003; 102: 2568-2573.
100. De Paepe P, Baens M, van Krieken H, et al. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 2003; 102: 2638-2641.
101. Delsol G, Lamant L, Mariamé B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 1997; 89: 1483-1490.
102. Karnan S, Tagawa H, Suzuki R, et al. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 2004; 39: 77-81.
103. Yamaguchi M, Ohno T, Oka K, et al. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol 1999; 105: 1133-1139.
104. Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002; 99: 815-821.
105. Harada S, Suzuki R, Uehira K, et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia 1999; 13: 1441-1447.
106. Kroft SH, Howard MS, Picker LJ, et al. De novo CD5+ diffuse large B-cell lymphomas. A heterogeneous group containing an unusual form of splenic lymphoma. Am J Clin Pathol 2000; 114: 523-533.
107. Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011; 117: 7070-7078.
108. Al-Sweedan SA, Neglia JP, Steiner ME, et al. Characteristics of patients with TEL-AML1-positive acute lymphoblastic leukemia with single or multiple fusions. Pediatr Blood Cancer 2007; 48: 510-514.
109. Suggs JL, Cruse JM, Lewis RE. Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias. ExpMol Pathol 2007; 83: 471-473.
110. Gorczyca W. Flow cytometry in neoplastic hematopathology. Taylor and Francis, London, New York 2006.
111. Abdelhaleem M. Frequent but nonrandom expression of myeloid markers on de novo childhood acute lymphoblastic leukemia. Exp Mol Pathol 2007; 83: 138-141.
112. Reid AG, Seppa L, von derWeid N, et al. A t(12;17)(p13;q12) identifies a distinct TEL rearrangement-negative subtype of precursor- B acute lymphoblastic leukemia. Cancer Genet Cytogenet 2006; 165: 64-69.
113. Johnsen HE, Bøgsted M, Klausen TW, et al., Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma. Cytometry B Clin Cytom 2010; 78: 338-347.
114. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
115. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98: 181-186.
116. Chiecchio L, Protheroe RK, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006; 20: 1610-1617.
117. Malavasi F, Deaglio S, Damle R, et al. CD38 and chronic lymphocytic leukemia: a decade later. Blood 2011; 118: 3470-3478.
118. Dürig J, Naschar M, Schmücker U, et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002; 16: 30-35.
119. Domingo-Domènech E, Domingo-Clarós A, Gonzàlez-Barca E, et al. CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients. Haematologica 2002; 87: 1021-1027.
120. Kröber A, Seiler T, Benner A, et al. V(H)mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410-1416.
121. Damle RN, Batliwalla FM, Ghiotto F, et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 2004; 103: 375-382.
122. Damle RN, Temburni S, Calissano C, et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007; 110: 3352-3359.
123. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001; 98: 1721-1726.
124. Montesinos P, Rayón C, Vellenga E, et al. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracyclinebased regimens. Blood 2011; 117(6): 1799-1805.
125. Gorczyca W, Sun ZY, Cronin W, et al. Immunophenotypic pattern of myeloid populations by flow cytometry analysis. Methods Cell Biol 2011; 103: 221-266.
126. Murray CK, Estey E, Paietta E, et al. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol 1999; 17: 293-297.
127. Ferrara F, Morabito F, Martino B, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 2000; 18: 1295-1300.
128. Ito S, Ishida Y, Oyake T, et al. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia. Leuk Lymphoma 2004; 45: 1783-1789.
129. Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 2000; 96: 2993-3000.
130. Katzenberger T, Petzoldt C, Höller S, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006; 107: 3407.
131. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results fromrandomized trials of the EuropeanMCL Network and the German Low Grade Lymphoma Study Group. Blood 2008; 111: 2385-2387.
132. Klapper W, Hoster E, Determann O, et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2009 Jun 16. [Epub ahead of print].
133. Catherwood MA, Matthews C, Niblock R, et al. ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia. Eur J Haematol 2006; 76: 294-298.
134. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1775.
135. Dürig J, Nückel H, Cremer M, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003; 17: 2426-2434.
136. Hüttmann A, Klein-Hitpass L, Thomale J, et al. Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status. Leukemia 2006; 20: 1774-1782.
137. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105-111.
138. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893-901.
139. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944-4951.
140. Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009; 23: 117-124.
141. Dierlamm J, Michaux L, Criel A, et al. Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications. Cancer Genet Cytogenet 1997; 94: 27-35.
142. Montserrat E. Treatment options in chronic lymphocytic leukemia. Hematol J 2004; 5 Suppl 1: S2-9.
143. Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 2009; 6: 405-418.
144. Stilgenbauer S. Advances in the use of alemtuzumab in CLL. Clin Adv Hematol Oncol 2008; 6: 23-24.
145. Montserrat E. Rituximab in chronic lymphocytic leukemia. Semin Oncol 2003; 30(1 Suppl 2): 34-39.
146. Chang H, Jiang AM, Qi CX. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia. Am J Clin Pathol 2010; 133: 70-74.
147. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
148. Byrd JC, Smith L, Hackbarth ML, et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 2003; 63: 36-38.
149. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278-3281.
150. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl JMed 2002; 346: 1937-1947.
151. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
152. Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma 2003; 44 Suppl 3: S41-7.
153. Lossos IS, Alizadeh AA, Eisen MB, et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci U S A 2000; 97: 10209-10213.
154. Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a ger- minal center B-cell gene expression profile. Blood 2002; 99: 2285-2290.
155. Gutiérrez-García G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011; 117: 4836-4843.
156. Vitolo U, Bertini M, Brusamolino E, et al. MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study. J Clin Oncol 1992; 10: 219-227.
157. Yan Y, Chan WC, Weisenburger DD, et al. Clinical and prognostic significance of bonemarrow involvement in patients with diffuse aggressive B-cell lymphoma. J Clin Oncol 1995; 13: 1336-1342.
158. Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation - a population-based study of 1575 cases. Br JHaematol 2004; 124: 151-159.
159. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011; 117: 2319-2331.
160. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114: 3533-3537.
161. Horning SJ. Natural history of and therapy for the indolent non- Hodgkin's lymphomas. Semin Oncol 1993; 20 (5 Suppl 5): 75-88.
162. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004; 22: 1454-1459.
163. Bastion Y, Berger F, Bryon PA, et al. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 1991; 2 Suppl 2: 123-129.
164. Bastion Y, Coiffier B. Is the International Prognostic Index for Aggressive Lymphoma patients useful for follicular lymphoma patients? J Clin Oncol 1994; 12: 1340-1342.
165. Coiffier B, et al. Prognostic factors in follicular lymphomas. Semin Oncol 1993; 20(5 Suppl 5): 89-95.
166. Davies AJ, Rosenwald A, Wright G, et al., Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol 2007; 136: 286-293.
167. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
168. Kondo E, Ogura M, Kagami Y, et al. Assessment of prognostic factors in follicular lymphoma patients. Int J Hematol 2001; 73: 363-368.
169. Decaudin D, Lepage E, Brousse N, et al. Low-grade stage IIIIV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients - a study of the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 1999; 17: 2499-2505.
170. Cameron DA, Leonard RC, Mao JH, Prescott RJ. Identification of prognostic groups in follicular lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Leuk Lymphoma 1993; 10(1-2): 89-99.
171. Federico M, Vitolo U, Zinzani PL, et al. Prognosis of follicular lymphoma: a predictivemodel based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000; 95: 783-789.
172. Maartense E, Le Cessie S, Kluin-Nelemans HC, et al. Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry. Ann Oncol 2002; 13: 1275-1284.
173. Siddiqui M, Ristow K, Markovic SN, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 2006; 134: 596-601.
174. Levine EG, Bloomfield CD. Cytogenetics of non-Hodgkin's lymphoma. J Natl Cancer Inst Monogr 1990: 7-12.
175. Tilly H, Rossi A, Stamatoullas A, et al. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 1994; 84: 1043-1049.
176. Goodlad JR, Krajewski AS, Batstone PJ, et al. Primary cutaneous follicular lymphoma: a clinicopathologic and molecular study of 16 cases in support of a distinct entity. Am J Surg Pathol 2002; 26: 733-741.
177. Goodlad JR, MacPherson S, Jackson R, et al. Extranodal follicular lymphoma: a clinicopathological and genetic analysis of 15 cases arising at non-cutaneous extranodal sites. Histopathology 2004; 44: 268-276.
178. Shia J, Teruya-Feldstein J, Pan D, et al. Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases. Am J Surg Pathol 2002; 26: 216-224.
179. Lorsbach RB, Shay-Seymore D, Moore J, et al. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood 2002; 99: 1959-1964.
180. Pittaluga S, Wlodarska I, Stul MS, et al. Mantle cell lymphoma: a clinicopathological study of 55 cases. Histopathology 1995; 26: 17-24.
181. Bosch F, López-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82: 567-575.
182. Meusers P, Engelhard M, Bartels H, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989; 7: 365-380.
183. Hiddemann W, Dreyling M. Mantle cell lymphoma: therapeutic strategies are different from CLL. Curr Treat Options Oncol 2003; 4: 219-226.
184. Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 2004; 83: 71-77.
185. Berinstein NL, Mangel J. Integrating monoclonal antibodies into the management of mantle cell lymphoma. Semin Oncol 2004; 31(1 Suppl 2): 2-6.
186. Brugger W, Hirsch J, Grünebach F, et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stemcell transplantation in follicular andmantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 2004; 15: 1691-1698.
187. Jacquy C, Lambert F, Soree A, et al. Peripheral blood stem cell contamination inmantle cell non-Hodgkin lymphoma: the case for purging? Bone Marrow Transplant 1999; 23: 681-686.
188. Andersen NS, Donovan JW, Borus JS, et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997; 90: 4212-4221.
189. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression- free survival. J Clin Oncol 2002; 20: 1288-1294.
190. Räty R, Franssila K, Joensuu H, et al. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 2002; 69: 11-20.
191. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558-565.
192. Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma - new biological insights and advances in therapy. Blood 1989; 73: 865-879.
193. Kyle RA. Why better prognostic factors for multiple myeloma are needed. Blood 1994; 83: 1713-1716.
194. Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsedmultiplemyeloma. Mayo Clin Proc 2004; 79: 867-874.
195. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489-3495.
196. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837-2840.
197. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandemstem-cell transplantation. Blood 2006; 108: 1724-1732.
198. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003; 101: 1520-1529.
199. Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence ofmetaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-termsurvival inmultiplemyeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 2003; 101: 3849-3856.
200. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007; 21: 529-534.
201. Appelbaum FR, Rowe JM, Radich J, Dick JE. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2001; 62-86.
202. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
203. Rathnasabapathy R, Lancet JE. Management of acute myelogenous leukemia in the elderly. Cancer Control 2003; 10: 469-477.
204. Farag SS, Archer KJ, Mrózek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006; 108: 63-73.
205. Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia 1995; 9: 1491-1498.
206. Grimwade D. The clinical significance of cytogenetic abnormalities in acutemyeloid leukaemia. Best Pract Res ClinHaematol 2001; 14: 497-529.
207. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004; 18: 115-136.
208. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into theMRC AML 10 trial. TheMedical Research Council Adult and Children's LeukaemiaWorking Parties. Blood 1998; 92: 2322-2333.
209. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
210. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
211. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acutemyeloid leukemia: results fromCancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
212. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
213. List AF, Sandberg AA, Doll DC. Myelodysplastic syndromes, inWintrobe's clinical hematology. Greer JP, Rodgers GM, et al. (eds.). Lippincott Williams and Wilkins, Philadelphia 2004; 2207-2234.
214. Bernasconi P, Alessandrino EP, Boni M, et al. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution, and survival. Am J Hematol 1994; 46: 270-277.
215. Bernasconi P, Boni M, Cavigliano PM, et al. Clinical relevance of cytogenetics in myelodysplastic syndromes. Ann N Y Acad Sci 2006; 1089: 395-410.
216. Bernasconi P, Klersy C, Boni M, et al. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia 2005; 19: 1424-1431.
217. Williams DL, Tsiatis A, Brodeur GM, et al. Prognostic importance of chromosome number in 136 untreated children with acute lymphoblastic leukemia. Blood 1982; 60: 864-871.
218. Kaspers GJ, Smets LA, Pieters R, et al. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995; 85: 751-756.
219. Look AT, Roberson PK, Williams DL, et al. Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia. Blood 1985; 65: 1079-1086.
220. Bloomfield CD, Goldman AI, Alimena G, et al. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood 1986; 67: 415-420.
221. Raimondi SC. Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 1993; 81: 2237-2251.
222. Jackson JF, Boyett J, Pullen J, et al. Favorable prognosis associated with hyperdiploidy in children with acute lymphocytic leukemia correlates with extra chromosome 6. A Pediatric Oncology Group study. Cancer 1990; 66: 1183-1189.
223. Harris MB, Shuster JJ, Carroll A, et al. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood 1992; 79: 3316-3324.
224. Heerema NA, Sather HN, Sensel MG, et al. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes). J Clin Oncol 2000; 18: 1876-1887.
225. Pui CH, Carroll AJ, Head D, et al. Near-triploid and near-tetraploid acute lymphoblastic leukemia of childhood. Blood 1990; 76: 590-596.
226. Heerema NA, Nachman JB, Sather HN, et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report fromthe children's cancer group. Blood 1999; 94: 4036-4045.
227. Raimondi SC, Zhou Y, Mathew S, et al. Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer 2003; 98: 2715-2722.
228. Forestier E, Johansson B, Gustafsson G, et al. Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: a Nordic series comparing two treatment periods. For the Nordic Society of PaediatricHaematology and Oncology (NOPHO) Leukaemia Cytogenetic Study Group. Br J Haematol 2000; 110: 147-153.
229. Pui CH, Carroll AJ, Raimondi SC, et al. Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid less than 45 line. Blood 1990; 75: 1170-1177.
230. Pui CH, Williams DL, Raimondi SC, et al. Hypodiploidy is associated with a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1987; 70: 247-253.
231. Cimino G, Elia L, Mancini M, et al. Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. Blood 2003; 102: 2014-2020.
232. Mancini M, Scappaticci D, Cimino G, et al. A comprehensi genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood 2005; 105: 3434-3441.